113 posts tagged with "pharma"

Overview​

The Friday, May 23, 2026 digest is dominated by ASCO preview activity, with multiple oncology companies announcing data presentations set for the upcoming conference in Chicago. Kelun-Biotech stands out with Phase III evidence supporting sac-TMT combined with pembrolizumab in first-line PD-L1 positive NSCLC, marking the first ADC combination to demonstrate a progression-free survival benefit against pembrolizumab monotherapy in this setting. The regulatory pipeline is also active, with Nuvalent filing for neladalkib approval and both Kelun-Biotech candidates under NMPA review in China. Meanwhile, the layoff tracker confirms continued industry consolidation, with BMS, Astellas, Replimune, and BioNTech each announcing workforce reductions tied to strategic shifts or regulatory setbacks.

Key Developments​

Kelun-Biotech presents dual NSCLC data sets at ASCO

Zimmer Biomet fda approval update

Kelun-Biotech will highlight two late-stage datasets at ASCO 2026, both now published in full abstracts. The Phase III OptiTROP-Lung05 trial (n=413) demonstrated that sac-TMT, the world's first TROP2 ADC approved for lung cancer, combined with pembrolizumab achieved a 70.2% objective response rate versus 42.0% for pembrolizumab alone as first-line treatment for PD-L1 positive advanced NSCLC, with progression-free survival hazard ratio of 0.35. The regulatory filing for this combination has been accepted for priority review by China's NMPA, and MSD is simultaneously running 17 global Phase III studies of the ADC outside Greater China. Separately, lunbotinib fumarate showed 87.1% ORR in pre-treated and 81.3% in treatment-naïve RET-fusion positive NSCLC patients in a Phase II pivotal study, with high intracranial response rates in brain metastasis patients; its NDA is also under NMPA review. The emerging competition in TROP2 ADC space against Gilead's Trodelvy is worth monitoring, particularly as global data from MSD's trials emerge.

Kelun-Biotech clinical trial update

Nuvalent advances ALK inhibitor toward FDA decision

Nuvalent phase 3 fail update

Nuvalent announced that pivotal neladalkib data from the ALKOVE-1 trial will be presented at ASCO (Abstract 8503, May 29), supporting the FDA NDA submission made in April 2026 for TKI pre-treated advanced ALK-positive NSCLC patients. The company is also running the Phase 3 ALKAZAR trial comparing neladalkib to alectinib in TKI-naïve patients, which could expand the drug's positioning earlier in the treatment paradigm. A separate presentation on zidesamtinib (Abstract 3108) will showcase preliminary data from the ARROS-1 trial showing activity across 15 response-evaluable patients with ROS1-positive solid tumors beyond NSCLC. Nuvalent's ALK-selective, TRK-sparing kinase inhibitor design aims to address brain metastases and resistance mutations while improving tolerability over existing TKIs. The FDA's decision timeline and ALKAZAR outcomes are the next catalysts to track.

Rigel clinical trial update

Rigel reports positive AcceleRET-Lung readout with safety signal to watch

AbbVie Inc. update

Rigel announced that the Phase 3 AcceleRET-Lung trial of GAVRETO (pralsetinib) met its primary progression-free survival endpoint and showed significantly greater overall response rates versus standard of care in RET fusion-positive NSCLC, with final data scheduled for oral presentation at ASCO (Abstract 8504, May 29). However, safety data revealed 8 infection-related deaths (7.4%) in the pralsetinib group versus zero in the standard of care arm, which will require careful physician assessment despite the company's position that increased monitoring can manage severe infection risk. Separately, REZLIDHIA (olutasidenib) demonstrated robust real-world effectiveness in relapsed/refractory mIDH1 AML patients post-venetoclax, with a 60.8% complete remission/complete remission with partial hematological recovery rate and median response duration of 30.3 months. Additional olutasidenib data and long-term survival outcomes (74% at 48 months) will be presented at the EHA Congress in June. The infection safety signal for GAVRETO warrants close attention as prescribers weigh benefit-risk.

Layoff tracker confirms continued industry restructuring

Bristol Myers Squibb is cutting 206 additional employees at its Lawrenceville, New Jersey site (effective July through December 2026), adding to 247 layoffs at the same location in February and over 1,200 job reductions across five separate events in 2025. Astellas Pharma is closing Universal Cells' Seattle office, affecting 50 employees, and consolidating cell and gene therapy operations to South San Francisco and Westborough, Massachusetts. Replimune announced 63 job cuts in Woburn, Massachusetts following the second FDA rejection of melanoma drug RP1. BioNTech is shutting its Singapore mRNA manufacturing plant by February 2027, affecting 85 workers, less than four years after acquiring the facility from Novartis. The pattern of manufacturing scale-backs and geographic consolidation continues across the industry, with mRNA technology facing ongoing headwinds.

Watchlist​

• React Health ventilator recall: The FDA classified the VOCSN V+Pro ventilator recall as most serious, with a manufacturing test error potentially causing undetected oxygen leaks that could reduce delivered oxygen or increase fire risk. Customers must stop use immediately. No serious injuries or deaths have been reported as of early March, but the device count affected remains unconfirmed. [link]
• Servier's vorasidenib three-year INDIGO follow-up: Updated Phase 3 data for VORANIGO in Grade 2 IDH-mutant glioma will be presented at ASCO, with sustained progression-free survival benefits and new quality-of-life analyses. A placebo-controlled trial in Grade 3 astrocytoma is also underway under Alliance leadership. [link]
• Innovent Biologics' IBI363 advances to Phase 3: The PD-1/IL-2α bispecific fusion protein demonstrated median OS of 18.2 months in squamous NSCLC (versus 9.4 months for docetaxel) and has entered a global Phase 3 trial (MarsLight-11) for IO-resistant squamous NSCLC. Takeda partnered on global co-development in October 2025. [link]
• Boehringer Ingelheim's HERNEXEOS expansion data: Zongertinib showed activity across HER2-driven tumors including 42% ORR in colorectal cancer, 62.5% in gastric cancer when combined with trastuzumab deruxtecan, and rapid symptom improvement in NSCLC. The DLL3/CD3 bispecific obrixtamig demonstrated 73% ORR in first-line extensive-stage small cell lung cancer. [link]
• Accent Therapeutics' ATX-295 first-in-human study: The oral KIF18A inhibitor targets chromosomal instability in aneuploid tumors and is enrolling patients with high-grade serous ovarian cancer and squamous NSCLC. A "Trial in Progress" poster will be presented at ASCO with no preliminary efficacy data yet released. [link]

Overview​

Thursday's session reflects a light news cycle with two substantively different catalysts: a late-stage biotech win for a rare pediatric indication and a serious medical device safety action. BioMarin's positive Phase 3 readout for VOXZOGO in hypochondroplasia marks the drug's expansion beyond its existing achondroplasia approval, potentially opening a new commercial frontier with no direct competition. Meanwhile, the FDA's Class I designation for Bolton Medical's Relay Pro stent-graft system underscores persistent risk in the thoracic aortic device space, with three reported deaths prompting immediate removal from the market. Both stories carry regulatory and commercial implications worth tracking into next week.

Key Developments​

BioMarin VOXZOGO passes Phase 3 in hypochondroplasia, FDA filing planned for Q3

Safety / Pharmacovigilance

BioMarin announced May 20 that its CANOPY-HCH-3 Phase 3 trial met the primary endpoint in children ages 3–17 with hypochondroplasia, showing a +2.33 cm/year improvement in annualized growth velocity versus placebo (p<0.0001). Secondary endpoints including standing height, height Z-score, and arm span also reached statistical significance at 52 weeks. The safety profile showed no new signals relative to the established achondroplasia dataset. The company plans to submit a supplemental New Drug Application to the FDA in Q3 2026, followed by filings to the EMA and other health authorities.

BioMarin clinical trial update

The readout matters because hypochondroplasia currently has no approved therapies in the U.S. or European Union, leaving a clear unmet need for the often-toddler-diagnosed population. Success here validates the C-type natriuretic peptide mechanism beyond the already-approved achondroplasia indication, potentially broadening VOXZOGO's commercial footprint substantially. Market participants should monitor for the timing of the sNDA submission and any signals from FDA regarding priority review designation, as a Q3 filing could position an approval decision in late 2026 or early 2027.

Bolton Medical's Relay Pro stent-graft receives Class I recall after three deaths

The FDA classified a recall for Bolton Medical's Relay Pro Thoracic Stent-Graft System as Class I on May 20, 2026, following an Early Alert issued April 28. The device's proximal clasp can detach, preventing graft release and necessitating open-surgery conversion in some cases. Three patient deaths have been reported—one from aortic perforation and two from fatal strokes during conversion surgery. The recall covers N4 non-bare stent configurations of 32mm and above, which have been removed from use and sale. Bolton Medical now operates under Terumo Aortic.

The recall matters because the Relay Pro is a widely used minimally invasive option for thoracic aortic aneurysms, dissections, and transections. Its removal narrows the therapeutic toolkit for vascular surgeons and leaves hospitals to pivot to alternative graft options, potentially accelerating market share shifts among competitors. Watch for any update from Terumo Aortic regarding a replacement or redesign timeline, and monitor whether additional adverse events emerge as the recall propagates through clinical workflows.

Watchlist​

• BioMarin: Full dataset presentation from CANOPY-HCH-3 at upcoming medical meeting; FDA filing confirmation in Q3. [link]
• Terumo Aortic / Bolton Medical: Updated communication to hospitals on affected inventory and patient monitoring protocols. [link]
• FDA: Any further Class I actions or safety communications from other device manufacturers in the vascular space.

Overview​

The May 20, 2026 digest reflects a light news cycle dominated by private financing rounds, with two substantial funding announcements in the radiopharmaceutical and immunology spaces. Healthcare-focused investors including OrbiMed and Vivo Capital continue deploying capital into clinical-stage assets, suggesting sustained appetite for differentiated therapeutic approaches despite broader market uncertainty. The absence of regulatory catalysts or major partnership announcements leaves the market interpreting deal flow as the primary signal. The Gargle dental marketing story, while outside traditional pharma, reflects the broader digital health infrastructure supporting provider visibility in an AI-driven search environment.

Key Developments​

Accro Bioscience closes $50M Series C for UC asset advancement. Accro Bioscience announced a $50 million Series C financing led by OrbiMed, with participation from TCGX, LAV, Cenova Capital and existing investors. The proceeds will advance AC-101, a RIPK2 inhibitor, into a Phase IIb trial for moderate-to-severe ulcerative colitis following FDA IND clearance. AC-101 has completed Phase I studies in Australia and China with favorable safety and PK/PD data, and an earlier Phase Ib/IIa proof-of-concept study in Chinese UC patients. The RIPK2 target operates in the NOD signaling pathway, positioning AC-101 as a potential oral alternative to injectable biologics for IBD patients. OrbiMed's leading role—given its $19 billion-plus AUM healthcare focus—may signal intent to facilitate future strategic partnerships or additional capital raises as the asset progresses. What to watch next: Phase IIb trial initiation timeline, enrollment targets, and whether OrbiMed's involvement attracts co-development interest from larger pharmaceutical companies seeking GI portfolio assets.

Gargle partnership update

Full-Life Technologies secures $150M to advance radiotherapeutic pipeline and manufacturing. Full-Life Technologies completed a $150 million financing package (approximately $110 million Series D equity plus $40 million debt) led by Vivo Capital, with participation from SK Biopharmaceuticals, Chengwei Capital, HSG, Junson Capital and other existing shareholders. The funding will advance two actinium-225 labeled radiotherapeutics: [225Ac]-FL-020 for prostate cancer and [225Ac]-FL-261 for multiple solid tumor indications. Separately, debt proceeds support operational and manufacturing scale-up, including plans to establish GMP-grade Actinium-225 manufacturing at Full-Life's Belgium facility to secure the radiopharmaceutical isotope supply chain internally. The company expects to have three differentiated clinical programs by end of 2026, all derived from its UniRDC discovery platform. What to watch next: timing of IND filings or clinical trial initiations for the lead assets, and whether the internal 225Ac manufacturing capability attracts partnership interest from other radiopharma developers seeking supply chain stability.

Accro Bioscience funding update

Gargle expands AI-enhanced marketing platform for dental practices. Gargle, Inc. announced an expanded AI-enhanced local visibility strategy for dental practices, integrating SEO, Answer Engine Optimization, Generative Engine Optimization, listings management, review management and patient conversion tools into a unified platform. The company positions itself as a full-service dental marketing agency responding to evolving patient search behavior that now incorporates AI-generated recommendations, voice search and Google Maps discovery alongside traditional website rankings. VP Brandie Lamprou emphasized that practices must "show up where those decisions are happening." The announcement lacks specific case studies, measurable outcomes or pilot data demonstrating effectiveness. What to watch next: whether Gargle can demonstrate client retention or patient acquisition metrics to support its differentiated positioning claims against competing dental marketing agencies.

Full-Life Technologies funding update

Watchlist​

• The digest contains only three stories, all announced on May 18, 2026, indicating a notably light news cycle for the coverage date. [link]
• Gargle's story falls outside traditional pharmaceutical or biotech sectors, representing digital health infrastructure rather than therapeutic development. [link]

Overview​

The May 18, 2026 pharma landscape shows continued momentum in AI-assisted drug discovery, with Harbour BioMed's first AI-designed candidate delivering preclinical body composition data that could position it competitively against established obesity treatments. Meanwhile, contract manufacturing relationships are deepening, as exemplified by LOTTE Biologics' expanded role with Ottimo Pharma, suggesting biotech sponsors are increasingly willing to invest in CDMO partnerships ahead of clinical readouts. The ACVR2A/2B pathway validated by prior bimagrumab data is now attracting next-generation entrants, while the broader metabolic space remains a focal point for combination strategies addressing GLP-1 limitations. Manufacturing capacity and process development capabilities are becoming differentiators as complex biologics advance through clinical pipelines.

Key Developments​

Harbour BioMed's LET003 Delivers Preclinical Body Composition Data in Obesity

Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Harbour BioMed announced preclinical results for LET003, its first AI-designed monoclonal antibody candidate targeting the ACVR2A/2B pathway. In obesity models, LET003 combined with semaglutide reduced fat mass by 76% versus vehicle and 34.7% versus semaglutide alone, while lean mass increased 5.7% compared to semaglutide monotherapy. Pharmacokinetic testing showed significantly slower blood clearance than comparators, and dose-ranging studies demonstrated LET003 at 5 mg/kg achieved lean mass effects comparable to bimagrumab at 15 mg/kg. The company plans to advance LET003 into clinical development for obesity treatment.

LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma

The data provide a proof-of-concept for the Hu-mAtrIx AI platform and establish a differentiated profile against the benchmark bimagrumab, particularly given the 10-fold potency differential and favorable pharmacokinetics that could support lower or less frequent dosing. The lean mass preservation angle addresses a known limitation of GLP-1 only approaches, potentially expanding the addressable patient population. However, preclinical mouse and monkey data require careful translation expectations, and the competitive landscape for ACVR2A/2B inhibitors remains active with other programs likely in development. Watch for the company's IND timeline and initial clinical study design, particularly how they plan to position LET003 relative to existing GLP-1-based regimens.

LOTTE Biologics Expands Manufacturing Partnership with Ottimo Pharma

LOTTE Biologics has expanded its agreement with Ottimo Pharma to include commercial process development and characterization activities for OTP-01, a PD-1/VEGFR2 biparatopic antibody. The work will be conducted at Lotte's Syracuse Bio Campus in New York. The original manufacturing agreement was signed in June 2025, and Ottimo Pharma recently initiated a Phase 1/2a study for OTP-01 with what it describes as industry-leading speed. LOTTE operates as a pure-play CDMO with dual manufacturing sites in the U.S. and South Korea.

The expansion reflects growing client confidence in Lotte's CDMO capabilities as OTP-01 advances towards commercialization, and signals a broader trend of biotech sponsors outsourcing not just manufacturing but also process development to specialized partners. Lotte's dual-site strategy provides supply chain redundancy that global biotech clients increasingly require. The inclusion of commercial process development activities suggests Ottimo is investing ahead of clinical data to compress timeline to market. Watch for Phase 1/2a enrollment progress and any updates on manufacturing scale-up plans, as well as further evidence of Lotte's ability to convert early-stage partnerships into long-term commercial relationships.

Watchlist​

• Harbour BioMed (HKEX: 02142) - LET003 IND filing timeline and initial clinical trial protocol
• CDMO sector capacity utilization trends as complex biologics programs advance through 2026
• Competitive landscape for ACVR2A/2B inhibitors entering obesity development

Overview​

The May 15, 2026 session featured two small-cap oncology companies reporting quarterly results and announcing corporate milestones. TuHURA Biosciences addressed its near-term financing concerns through a $50 million credit facility while advancing its Phase 3 Merkel cell carcinoma program and securing FDA orphan drug designation for a melanoma indication. Citius Oncology continued commercial scaling of LYMPHIR, which launched in December 2025, achieving strong formulary penetration and payer coverage while raising capital to fund operations into late 2026. Both companies are navigating the challenging transition from clinical-stage to commercial entities, with funding strategies and enrollment progress serving as key risk factors.

Key Developments​

TuHURA Biosciences secured a $50 million non-equity credit facility from its largest stockholder, removing near-term financing pressure and extending cash runway into 2028 based on current burn rates. The facility carries a 12% annual interest rate with maturity in April 2031. The company ended Q1 2026 with $6.3 million in cash and quarterly net cash outflows of $4.4 million. The financing ensures the Phase 3 registration trial of IFx-2.0 as adjunctive therapy to Keytruda in Merkel cell carcinoma can proceed through anticipated top-line data in H2 2027. FDA granted Orphan Drug Designation for IFx-2.0 in stage IIB to IV cutaneous melanoma based on Phase 1 safety data showing clinical benefit in checkpoint inhibitor-refractory patients, potentially providing seven years of market exclusivity upon approval. The company also appointed Amanda Garofalo as SVP of Clinical Operations and engaged Craig Tendler for strategic and CMO-level services. Watch for Phase 3 enrollment milestones and FDA IND meeting outcomes for the TBS-2025 VISTA inhibiting antibody program entering Phase 1b/2 in NPM1-mutated AML.

TuHURA Biosciences clinical trial update

Citius Oncology reported $1.7 million in Q2 FY2026 net revenue from LYMPHIR, with $5.6 million for the first half since the December 2025 launch. The commercial rollout has progressed rapidly, with 83% of target accounts achieving formulary inclusion or active review and payer coverage approaching 100% of commercial lives with no reimbursement denials reported. Patients are beginning to transition from academic centers to community infusion centers, representing an important next phase for broader market penetration. Subsequent to quarter-end, the company secured up to $36.5 million in combined debt and equity financing, including a $25 million senior secured credit facility with $10 million funded at close and up to $15 million available pending milestone achievements. LYMPHIR also entered European markets through Uniphar Named Patient Programs across 19 markets. Positive Phase 1 data from two investigator-initiated studies showed clinical activity when LYMPHIR was combined with pembrolizumab in gynecologic cancers and administered prior to CAR-T therapy in DLBCL, positioning the asset as a potential platform technology. The company expects sufficient funds to continue operations through November 2026. Watch for repeat order patterns as initial accounts mature and the $15 million milestone-based financing tranche.

Citius Pharmaceuticals, Inc. funding update

Watchlist​

• FDA engagement timelines for Mino-Lok and Halo-Lido programs remain undisclosed [link]
• Long-term clinical durability data from LYMPHIR combination studies not yet available [link]
• Lead ADC candidate selection for proof-of-concept studies in AML still pending at TuHURA
• Revenue trajectory for LYMPHIR may face quarter-over-quarter volatility as distributor inventory normalizes

Overview​

The pharma landscape this session reflects a sector in transition, with Alzheimer's disease research leading the narrative. Biogen's tau-targeting antisense oligonucleotide diranersen delivered mixed Phase 2 results—missing its primary endpoint while posting secondary signals that kept the program alive. The broader Alzheimer's pipeline is visibly diversifying, with three-quarters of current trials now pursuing non-amyloid, non-tau pathways, suggesting the field is maturing beyond its initial amyloid hypothesis bet. Meanwhile, smaller-cap immuno-oncology players like TuHURA Biosciences continue to access creative financing structures and regulatory designations that could reshape their development timelines. The tape is light with only three candidate stories, and one—Citius Pharmaceuticals—lacks sufficient detail for thorough coverage.

Key Developments​

Biogen's Diranersen Misses Primary Endpoint but Generates Downstream Signals in Phase 2 CELIA Study

The ADDF clinical trial update

Biogen announced May 14 that its Phase 2 CELIA study evaluating diranersen—an antisense oligonucleotide targeting tau—in early Alzheimer's disease did not meet its primary endpoint, though specifics were not disclosed. Secondary outcomes showed reductions in tau burden and preliminary signals of slowed cognitive decline. The company plans to advance the asset into further trials despite the top-line miss. ADDF leadership characterized the results as an "encouraging signal" and a milestone toward combination therapies, noting the broader Alzheimer's pipeline is "becoming broader, deeper, and more ambitious." Diranersen represents the first therapy of its kind to reach this stage, offering early proof of concept for tau-targeting via antisense mechanism. A successful tau-targeted approach would enable combination strategies alongside existing anti-amyloid therapies. The field's shift toward precision medicine is underscored by the fact that 75% of current Alzheimer's trials target pathways beyond amyloid and tau—including inflammation, metabolic dysfunction, and oxidative stress. Full data presentation is scheduled for the Alzheimer's Association International Conference, July 12–16, 2026, in London.

TuHURA Biosciences clinical trial update

TuHURA Biosciences Secures $50M Credit Facility and Receives FDA Orphan Drug Designation for IFx-2.0

Citius Pharmaceuticals, Inc. funding update

TuHURA Biosciences reported first-quarter 2026 results alongside several corporate updates. The company entered a $50 million non-equity credit facility with its largest stockholder, bearing a 12% annual interest rate and maturing April 21, 2031, extending cash runway into 2028. The FDA granted Orphan Drug Designation for IFx-2.0 in stage IIB to IV cutaneous melanoma based on Phase 1 data demonstrating safety and clinical benefit in checkpoint inhibitor-refractory patients—a designation that qualifies for tax credits, study grants, and seven-year market exclusivity upon approval. Leadership additions include Craig Tendler, M.D. providing Chief Medical Officer-level strategic services while remaining on the board, and Amanda Garofalo as Senior Vice President of Clinical Operations. Cash stood at $6.3 million at quarter-end, with Q1 R&D expenses of $5.2 million. The company is advancing toward an FDA IND meeting for its TBS-2025 VISTA inhibitor in the first half of 2026 and initiating a Phase 1b/2 trial in molecularly defined AML subsets in the second half. Phase 3 enrollment for IFx-2.0 as an adjunct to Keytruda in first-line advanced Merkel Cell Carcinoma is targeted for completion in the second half of 2027.

Watchlist​

• Full CELIA study data — Tau reductions and cognitive signals warrant close review once presented at AAIC 2026; clinical meaningfulness remains unconfirmed pending detailed disclosure. [link]
• TuHURA enrollment progress — Phase 3 accrual rates for IFx-2.0 in Merkel Cell Carcinoma will be a key catalyst read as the year progresses. [link]
• FDA IND outcome for TBS-2025 — VISTA inhibitor entering AML development represents a differentiated play; IND meeting outcome expected first half 2026.

Overview​

Friday's session was quiet by historical standards, with the tape dominated by two company-specific catalysts rather than any macro or regulatory shift. The standout was Biogen's Phase 2 CELIA readout for its tau-targeting therapy diranersen—technically a miss on the primary endpoint, but featuring biomarker signals and cognitive trends that Biogen and ADDF leaders characterized as clinically meaningful enough to justify advancing the program. Meanwhile, a newly formed Australian medtech company NinaMED closed a $13.75 million financing round to develop a non-invasive neuromodulation device for overactive bladder, an asset licensed from Toronto-based EBT Medical. The day's pipeline activity underscores a broader shift toward combination approaches in neurology and device-based alternatives in urology, though neither story moves the market absent a catalyzing event.

Key Developments​

Biogen's Tau Program CELIA Misses Endpoint But Biomarkers Spur Continuation. Biogen announced May 14 that its Phase 2 CELIA study evaluating diranersen in early Alzheimer's disease did not meet the primary endpoint. Despite the miss, the study showed reductions in tau biomarkers and signals of slowed cognitive decline, prompting Biogen to plan advancement into further trials. ADDF leadership called the readout an encouraging signal and noted the Alzheimer's pipeline is now "broader, deeper, and more ambitious" than prior generations. Diranersen represents the first therapy of its kind to reach this stage of development, offering early proof of concept that targeting tau could yield both biological and clinical effects. The full topline dataset will be presented at the Alzheimer's Association International Conference in London, July 12–16. What to watch: whether the full dataset reveals clinically meaningful differentiation against standard of care, and whether Biogen can map a viable regulatory path given the ambiguous primary endpoint read-through.

The ADDF clinical trial update

NinaMED Secures $13.75 Million to Advance Wearable OAB Device. NinaMED, a newly formed Australian medtech company, announced completion of a $13.75 million financing round led by SPRIM Global Investments, with participation from SV Health Investors. The proceeds will fund development and an Investigational Device Exemption application for the NiNA System®, a non-invasive wearable neuromodulation device targeting the saphenous nerve for overactive bladder. NinaMED holds exclusive global rights from EBT Medical, which originally developed the technology at the University of Toronto. The company appointed Ian Meredith, former EVP and Global Chief Medical Officer at Boston Scientific, as board chair. The OAB market serves an estimated 550 million patients worldwide who currently rely on pharmaceuticals or invasive neuromodulation. What to watch: the IDE submission timeline and whether early clinical data can establish competitive efficacy and safety versus existing therapies.

EBT Medical and NinaMED funding update

Watchlist​

• The ADDF noted that 75% of current Alzheimer's trials target pathways beyond amyloid and tau—including inflammation, metabolic dysfunction, and oxidative stress—suggesting the field is broadening even as single-target programs continue to generate data. [link]
• SV Health Investors remains a long-standing backer of EBT Medical and maintains a board seat, signaling ongoing institutional commitment to the technology platform beyond the NinaMED spinoff. [link]

Overview​

May 14, 2026 — The digest is light today, with two substantive company-specific developments carrying through from the morning window. The stories both originated from PR Newswire and span the biotech and medtech subsectors without any clear thematic throughline. Kelun-Biotech's dual regulatory progress in China and the US for a bispecific PD-1/VEGF antibody reflects continued cross-border development activity in oncology, while the NinaMED financing round signals investor appetite for novel neuromodulation approaches targeting overactive bladder. No broader sector catalysts or regulatory announcements moved the tape today.

Key Developments​

Kelun-Biotech gains dual regulatory clearance for bispecific antibody candidate. Kelun-Biotech received IND approval from China's CDE for SKB118, a bispecific antibody targeting PD-1 and VEGF, marking the second regulatory milestone for this asset in recent months. The FDA had already cleared the IND in January 2026, enabling the global ASCEND Phase I/II trial (NCT07335497) to proceed with enrollment of up to 290 patients with locally advanced or metastatic solid tumors. A December 2025 collaboration with Crescent Biopharma gave Kelun-Biotech exclusive rights to develop and commercialize SKB118 in Greater China. The company is exploring combining SKB118 with its proprietary ADC assets under an "ADC+IO" strategy, as preclinical data suggests anti-VEGF activity may improve tumor vasculature and enhance ADC delivery. Watch for whether the Chinese trial protocol mirrors the US study and when initial Phase I safety data might emerge.

Kelun-Biotech fda approval update

NinaMED secures $13.75M to advance wearable neuromodulation device for overactive bladder. NinaMED, a newly formed Australian company, closed a financing round led by SPRIM Global Investments to advance the NiNA System, a non-invasive wearable device targeting the saphenous nerve in the upper calf for treatment of overactive bladder. The device is licensed on an exclusive global basis from EBT Medical, a Toronto-based neuromodulation developer. The financing will support preparation of an IDE application and operational buildout in Australia, with the board chaired by Professor Ian Meredith, former EVP and Global Chief Medical Officer at Boston Scientific. The OAB market affects an estimated 550 million patients worldwide, and the saphenous nerve approach offers a potentially more comfortable alternative to existing sacral or tibial stimulation therapies while avoiding systemic drug side effects. Watch for IDE submission timing and whether pivotal trial design yields competitive efficacy and safety profiles against standard pharmacological therapies.

EBT Medical and NinaMED funding update

Watchlist​

• FDA MedWatch and BioSpace contributed to the morning window but did not produce carry-through developments today. [link]
• Monitor for additional regulatory filings or data readouts from the ASCEND trial in coming months. [link]

Overview​

The May 13 session produced a light news cycle with two substantive developments spanning regulatory advancement in oncology and a consumer health safety recall. The dominant theme tilted toward pipeline and platform news rather than landmark clinical data, with signal emerging primarily from wire services and FDA announcements. China's Kelun-Biotech secured parallel regulatory clearance for a bispecific antibody candidate, enabling synchronized development across the world's two largest pharmaceutical markets, while a Wisconsin manufacturer pulled an over-the-counter eczema treatment over microbial contamination. The tape offered little broader sector direction, leaving investors to parse company-specific catalysts in an otherwise quiet session.

Key Developments​

Kelun-Biotech won CDE IND approval for SKB118, a bispecific antibody targeting PD-1 and VEGF for advanced solid tumors. The May 12 clearance from China's Center for Drug Evaluation grants Kelun-Biotech the ability to conduct parallel clinical trials in China alongside the global ASCEND Phase I/II trial already initiated in the U.S. in January. The company acquired exclusive Greater China rights to SKB118 (also designated CR-001) from Crescent Biopharma in December 2025 and is positioning the candidate within an "ADC+IO" strategy, leveraging the dual mechanism—PD-1 blockade to restore T-cell tumor recognition and VEGF inhibition to normalize tumor vasculature—to potentially enhance delivery of its proprietary ADC assets. Early clinical data readouts from the ASCEND trial, which plans to enroll up to 290 patients, will be the next meaningful inflection point.

Kelun-Biotech fda approval update

Pharmacal issued a nationwide recall of MG217 Multi-Symptom Treatment Cream after internal testing detected Staphylococcus aureus in a single lot. The recall covers lot 1024088 (expiration November 2026) of the 6-oz eczema cream distributed through wholesale channels, HE-BUTT Grocery, and Amazon, with the FDA posting the notice on May 12. No adverse events have been reported, though the contaminant poses infection risk—particularly for immunocompromised users who could develop serious skin, soft-tissue, or systemic complications. The recall surfaces manufacturing quality concerns for topical OTC products and may invite increased FDA scrutiny of the Jackson, Wisconsin facility. Stakeholders should watch for any expansion of the recall to additional lots or regulatory action stemming from the investigation.

Safety / Pharmacovigilance

Watchlist​

• No additional items met threshold for inclusion in today's session. [link]

Overview​

The two key developments today cover a logistics company's quarterly performance and a university research initiative. Radiant Logistics reported flat Q3 revenue but significantly improved net income, with domestic freight showing early signs of supply-driven recovery while international operations face headwinds from tariffs and Red Sea disruptions. University of Oklahoma launched Project 200, a major research initiative targeting health, weather, security, and energy research with ambitions to generate $100M in annual federal funding and join the elite Association of American Universities consortium. Neither story involves traditional pharmaceutical companies, and the pipeline appears light for healthcare-specific developments today. The divergent signals—one sector grappling with trade policy uncertainty while an academic institution is expanding research capacity—suggest uneven momentum across the broader health ecosystem.

Key Developments​

Radiant Logistics Q3 FY2026 Results Radiant Logistics reported Q3 FY2026 results on May 11 with revenue flat at $214.1M year-over-year, though net income nearly doubled to $4.7M ($0.10/share) from $2.5M ($0.05/share). Adjusted EBITDA declined 17% to $7.8M with margin contracting 240 basis points to 13.8%, as cost investments offset pricing gains. The company highlighted domestic freight recovery driven by carrier attrition and driver shortages, while international operations face dual headwinds from sweeping U.S. tariff changes and ongoing Red Sea shipping disruptions that have closed the Strait of Hormuz and Suez Canal to major carriers. Net income growth was boosted by lower taxes and one-time items, while adjusted net income fell 24%, highlighting underlying cost pressures despite the headline profit improvement. The company is advancing its Navegate platform and AI agent "Ray" as competitive differentiators to navigate trade complexity and compliance requirements. Domestic freight appears to be reaching an inflection point with improving truckload and intermodal rates, which should benefit Radiant's domestic operations in coming quarters if the recovery proves sustainable. Permanent U.S. tariff structures expected before July could significantly alter trade economics, and the scope and duration of Red Sea disruptions remain unconfirmed.

RADIANT LOGISTICS ANNOUNCES RESULTS FOR THE THIRD FISCAL QUARTER ENDED MARCH 31, 2026

University of Oklahoma Project 200 University of Oklahoma announced Project 200 on May 11, a generational initiative to recruit approximately 200 world-class researchers across health, extreme weather, national security, and energy by 2032. The initiative targets nearly $100M in new annual federal research funding by 2032 and aims to help the university exceed $1B in annual research expenditures, supporting more than 2,000 new jobs and generating approximately $95M in new state and local tax revenue over the decade. OU has set ambitious health goals including reducing cancer mortality by 10% and diabetes-related deaths by 30% through expanded clinical trials and precision medicine, addressing Oklahoma's disproportionately high rates of these conditions. The university is pursuing Association of American Universities membership to elevate its national profile and attract additional federal funding and partnerships. The initiative builds on OU's research momentum, which has grown 70% over the past six years—the fastest pace in five decades—and arrives when many universities nationwide are contracting, potentially allowing OU to gain competitive advantage in research talent acquisition. Whether OU can successfully recruit all 200 targeted researchers and achieve its health outcome targets remains unconfirmed, and the total financial investment required for Project 200 was not specified.

University of Oklahoma Launches Project 200, a Generational Investment in Oklahoma's Future

Watchlist​

• Sustainability of domestic freight recovery cycle—market improvements not yet reflected in Q3 results
• Timeline, cost, and revenue impact of Radiant's AI agent "Ray" remain unconfirmed
• OU's success in recruiting all 200 researchers and achieving AAU membership timeline
• Federal research funding availability and political conditions affecting OU's projections
• Impact of nearshoring and trade diversification on freight volume trajectories